11:18 AM EDT, 08/15/2025 (MT Newswires) -- Pfizer ( PFE ) said Friday that a phase 3 study of its investigational drug inclacumab in patients with sickle cell disease did not meet its primary endpoint of significant reduction in the rate of vaso-occlusive crises over a 48-week period.

Pfizer ( PFE ) said it is continuing development of its broader sickle cell disease portfolio, including Oxbryta and osivelotor.

Price: 25.13, Change: +0.02, Percent Change: +0.09